Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell‐free DNA for detection and monitoring of extramedullary AML relapse

1 Mar 2025

Abstract excerpt

Abstract Isolated extramedullary manifestations (IEM) of acute myeloid leukemia (AML) are recurrent events, especially following allogeneic hematopoietic cell transplantation (alloHCT). To date, measurable residual disease (MRD) assessment for this difficult‐to‐treat patient cohort has not been established. In this study, we evaluated highly sensitive next‐generation sequencing (NGS) of IEM‐AML tumor and compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40066001
DOI: 10.1002/hem3.70097

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell‐free DNA for detection and monitoring of extramedullary AML relapsePMID 40066001Read ↗

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemiaSemantic proximity Read ↗

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read ↗

Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.Semantic proximity Read ↗

Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes.Semantic proximity Read ↗

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity Read ↗

Personalized Circulating Tumor DNA (ctDNA) Profiling Enables Superior and Universal Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML)Semantic proximity Read ↗

Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNASemantic proximity Read ↗

Single-cell mutational profiling enhances the clinical evaluation of AML MRD.Semantic proximity Read ↗

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic TransplantationSemantic proximity Read ↗

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemiaSemantic proximity Read ↗

Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse.Semantic proximity Read ↗

Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.